Acute Ischemic Stroke; Brief Overview of implementation of Thrombolysis and Thrombectomy Treatments

Omar Khashaba *, Ibrahim Abdelaziz Libida, Mohamed Hamed Abo Warda, Ahmed AbdelAziz El Sammak

Diagnostic Radiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Email: omarmetwally@zu.edu.eg, oakhashaba@gmail.com

Abstract

Background: The probability of a complete and disability-free recovery from an acute ischemic stroke is considerably increased by reperfusion, whether it be accomplished through intravenous thrombolytic drug therapy or, in some cases, endovascular mechanical thrombectomy. Intravenous thrombolysis is becoming less common due to the limited window of opportunity for therapy, and each patient must assess the possible advantages against the dangers of symptomatic cerebral haemorrhage. Pre-hospital and in-hospital paths should be optimized because shorter onset-to-reperfusion periods are more advantageous. While hemorrhage is more common in more severe strokes, a higher percentage of patients are disability free after therapy unless they suffer from a hemorrhagic consequence. There are a few rare side effects include swelling of the face, tongue and extra-cranial bleeding. Individuals who have substantial arterial blockage seen on imaging may occasionally benefit from endovascular mechanical thrombectomy. Effective treatment plans require well-coordinated services that can deliver care quickly in settings with the required resources (staff and equipment). It surges the incidence to return to independence greatly when a patient receives an intravenous recombinant tissue plasminogen activator (IV rtPA) within 4.5 hours of the spawn of symptoms. Shorter onset-to-treatment periods are associated with greater benefits; thus services should reduce treatment delay as much as possible. The most serious side effect of IV rtPA is symptomatic cerebral haemorrhage. The choice of treatment depends on weighing the likelihood of a positive clinical outcome against the danger of cerebral bleeding. A subgroup of large vessel occlusion patients benefits from endovascular mechanical thrombectomy in terms of their odds of a successful outcome. Endovascular operations can have vascular access, radiographic contrast media and vascular damage as side effects.

Keywords: Thrombolysis, Thrombectomy, Stroke

Introduction

If blood flow is quickly restored following the commencement of an acute ischemic stroke, brain tissue may be saved. The likelihood of a full recovery without disabilities can be considerably increased by intravenous recombinant tissue plasminogen activator (IV rtPA) and endovascular thrombectomy employing stent retrievers.

Intravenous thrombolysis:

When IV rtPA is administered up to 4.5 hours after the onset of symptoms, there is a considerably higher chance that the patient would recover to independence, according to a meta-analysis of pooled patient data from 6,756 patients in 9 randomized controlled trials. The number needed to treat (NNT) for an excellent functional outcome is five for treatment within 90 minutes, nine for treatment within 91-180 minutes, and 19 for treatment within 181-270 minutes after onset. The likelihood of a favorable outcome drops quickly with longer onset-to-treatment periods.1

Clinically difficult diagnoses, a narrow treatment window, and the requirement to individually weigh risk and benefit while taking into consideration relative contraindications continue to constrain clinical use of IV rtPA.2 However, service organization that optimize transfer routes can make 20% of patients eligible under the standards in place right now.3 Nevertheless, several 'legacy' contraindications resulting from earlier clinical trials and are even included on the prescription label have been replaced owing to the evidence of comparable efficacy and safety.4 (Fig 1) Regarding the decline in disability, the primary prognostic endpoint after stroke, IV rtPA had a net positive effect across all severity and age strata.

Type	No.	Eligibility Recommendations
Indications	1	Symptoms of neurological impairment caused by ischemic stroke
	2	Within 3 h of ischemic stroke symptom from onset or patient last known well or at baseline state.
	3	Patients older than 18 years
	4	Informed consent signed by patient or family member
Contraindications	1	Intracranial hemorrhage
	2	With history of intracranial hemorrhage
	3	Stroke or severe head injury within 3 months
	4	Intracranial neoplasms or giant intracranial aneurysms
	5	Intracranial or intraspinal surgery within 3 months
	6	Received large surgery within 2 weeks
	7	Gastrointestinal bleed or urinary system hemorrhage within 3 weeks
	8	Associated with active visceral hemorrhage
	9	Associated with aortic arch dissection
	10	Arterial punctures with difficult to hemostasis in the past week
	11	Blood pressure > 180/100 mmHg
	12	Platelet count < 100* 10^9/L
	13	Treatment with low-molecular-weight heparin within 24 h
	14	international normalized ratio (INR) > 1.7 or Prothrombin time (PT) > 15 s
	15	Treatment with thrombin inhibitors or factor Xa inhibitors within 48 h, or abnormal laboratory examinations
	16	Blood glucose < 2.8 mmol/L or blood glucose > 22.22 mmol/L
	17	Large area of head infarction

Fig 1. Thrombolysis indications and contraindications.

Indications and contraindications:

Therapy choices should include each patient's risk-benefit balance and could be guided by modified RCT data that illustrates outcomes in various severity strata and time from onset to treatment.5 While the benefit of therapy changes with time to treatment and ought to be weighed versus the risk of symptomatic intracerebral haemorrhage (SICH), the relative benefit of therapy is consistent along various age groups and severities. Over the course of the first 4.5 hours, the relative risk of SICH seems stable. Absolute SICH risk rises when the stroke severity increases since it is correlated with both the severity of the stroke and the occurrence of older brain abnormalities such as old infarctions. However, risk factors for SICH also indicate a worse prognosis for strokes that go untreated (e.g., old age, diabetes, intense stroke, older computerized tomography (CT) changes) and overall treatment effect is consistent across all of these subgroups.

Further clinical trials are needed since effects in mild stroke of NIHSS score 5 (National Institutes of Health Stroke Scale), are not properly characterised.6 Neurological scores should not take precedence over clinical assessment because even low NIHSS scores can indicate very serious problems (as isolated dysphasia or total hemianopia), while considerably high NIHSS scores (>25) are typically linked with stroke of the posterior circulation.7

To rule out established recent ischemia and intracranial bleeding, brain imaging is crucial. There are not enough data on efficacy or safety in patients with other anatomical defects as these illnesses were largely left out of clinical trials to guarantee accurate diagnosis. Although the treatment impact of IV rtPA is not different in this subset, the presence of structurally significant hypodensity is a signal of severe irreversible ischemia (a "large ischemic core") and indicates a worse prognosis.8,9 CT or MR imaging, either as angiography or perfusion, can distinguish between established infarction and the penumbra (potentially reversible ischemia) and provides data on intracranial arteries and cerebral perfusion.10 Even though imaging characteristics, particularly a significant umbra (ischemic core) and weak collateral channels, are heavily linked to prognosis,[11] an interference with the effect of treatment is not set.[12]

In situations of considerable risk of systematic or intracranial bleeding, treatment is contraindicated.13 among which are coagulopathies and high blood pressure (>185 mmHg systolic or >110 mmHg diastolic). Case-control studies, registries and large case series demonstrate that thrombolysis is equally safe and effective in a variety of clinical circumstances that were formerly thought to be relative contraindications, such as diabetes a history of prior stroke >6 weeks ago, a dissection stroke, subacute silent stroke, elevated blood pressure within the range of 180/110 mmHg, high INR (international normalized ratio) of 1.7, myocardial infarction more than 7 weeks. The third International Stroke Trial (IST-3) enrolled subjects with a wider variety of baseline characteristics than previous trials to determine the efficacy and concluded that there is no considerable alteration of therapy effect by a number of parameters, such as early ischemic change on CT, presence of leukoaraiosis, blood glucose, baseline blood pressure, stroke severity, previous therapy, and baseline age.9

Complications:

At trauma sites (such as venipuncture sites, gums, the oropharynx, and areas of mild trauma), modest systemic bleeding is frequent. The complication that is most likely to be functionally significant is SICH. According to the definition, the frequencies of SICH vary from 2-6% for the commonly used European Acute Stroke Studies that interrogate imaging differentiation of ICH (Fig 2), which is paired in study reports with clinical change in different ways. Only bleeding from parenchymal haematoma type 2 has been independently linked to a poor prognosis, whereas reperfusion is linked to hemorrhagic infarction.11,14 Multiple factors raise the likelihood of SICH,15,16 however the severity of the stroke is the best indicator (regardless thrombolysis or not).17 For NIHSS 0–4, the excess risk of SICH increases to 1.5%; for NIHSS > 25, it increases to 3.7% (Fig2).



Fig 2.

The National Institutes of Health Stroke Scale (NIHSS) measures the possibility of symptomatic intracerebral haemorrhage (SICH) and the absolute rise in the subset of subjects with remarkable functional outcome at 3-6 months following stroke. These show the differences in outcomes between patients who received intravenous recombinant tissue plasminogen activator (IV rtPA) treatment versus the control cohort after treatment delay and age had been taken into account. Treatment delay and age were taken into account while modelling high SICH risks for NIHSS grouping. Information obtained from Whiteley et al.17

Rates of extra-cranial haemorrhage following IV rtPA ranged from 2–7%, although no standard definition was applied, and the course of treatment was determined by the location and amount of bleeding.18

1-8% of patients taking IV rtPA experience orolingual angioedema, which is an idiosyncratic acute swelling of the tongue and lips, usually linked to previous angiotensin converting enzyme inhibitor medication. Cases might happen a few minutes to several hours after therapy. About 70% of instances are considered light, while only 12% are severe enough to interfere with breathing. Most cases get better on their own, with the help of steroids, or on using antihistamines.19 It is uncommon to hear about such side effects to using IV rtPA.20



Fig 3.

Heidelberg Bleeding Classification: classification of haemorrhages following thrombolysis.

A: small marginal petechial haemorrhage.

B: Area of petechial haemorrhage, yet no mass effect.

C: Intra-axial blood clot < a third of parenchyma.

D: Intra-axial blood clot > a third of the parenchyma.

Higher than double as often as SICH, non-haemorrhagic causes (such as recurrent ischemic stroke, brain edema, or sudden deterioration) are to blame for neurological determent after IV rtPA.21 The presence of a systemic ailment, such as hypoxia, infection, or other treatable reasons, may exacerbate a patient's neurological situation.

Mechanical endovascular thrombectomy (EVT):

If there is a blockage of the main intracranial vessels (15% of the terminal ICA or 20% of the MCA)22 and if there is a significant clot burden, early recanalization following IV rtPA is uncommon. Because of this, occlusions of these locations are linked to extremely poor stroke and worse prognosis. Even though IV rtPA has the lowest risk of early recanalization, in 5 RCTs published in 2015, EVT was found to be beneficial in such population of patients, with considerably better outcome against the standard medical practice alone.

Using CT angiography, patients with major artery blockage were chosen for all trials. Using perfusion or vascular collateral imaging, extra selection to enrich the population was carried out in three experiments. Initiation of IV rtPA was reached within 1-2 hours after commencement, and reperfusion was completed in a median of 4-6 hours following onset thanks to the highly organized, high-volume neurovascular services provided by those centers. In the MR CLEAN experiment, significant therapeutic effects were lost with the more time between the start of symptoms and reperfusion even if within the 6 hours mark.24

Few patients were randomly assigned after six hours in several trials, despite ostensibly greater time periods for inclusion (8 and 12 hours in REVASCAT and ESCAPE, respectively). No indication of a difference in treatment response by age group, clinical severity, eligibility for IV rtPA or vascular blockage site was found. On those who had severe early CT abnormalities or a handicap from birth, there were surprisingly limited data. Also, in order to establish whether vascular access to the target occlusion is achievable, CT angiography should incorporate extra-cranial vessel imaging.

Endovascular operations can have vascular access complications, contrast media complications, and device-related vascular damage complications. In a non-randomized, post-hoc comparison, general anesthesia use was linked to a worse outcome than sedation, and additional studies are being conducted to investigate this.25 Complications at the puncture site, like hematoma or haemorrhage, can happen.26 According to the MR CLEAN trial, relevant procedural complications included a 5.2% excess incidence of new ischemic stroke in another vascular territory, 8.6% embolization into new territories outside the target downstream territory of the occluded vessel, 1.7% procedure-related vessel dissections, and 0.9% vessel perforations resulting in subarachnoid or intracerebral haemorrhage.27,28 Overall, none of the most recent IAT trials showed an overabundance of SICH. The clinical trial complication rates reflect routine practice in specialized neurovascular centers, nearly always performed by interventional neuroradiologists; it is unknown whether the same problem rates will apply to other operators or service configurations.

It is logistically difficult to integrate mechanical thrombectomy into routine stroke therapy. 10-15% of patients who received rtPA are likely to be eligible for therapy. IAT centres and operators must handle enough cases to keep their effectiveness and level of service high.29 Depending on the population density and the regional distribution of resources and experience, certain clinical and imaging criteria should trigger patient transfer to a neuro-interventional stroke centre.30

Conclusions:

Functional outcomes are improved after reperfusion with intravenous thrombolysis or endovascular mechanical thrombectomy, but the benefits of both treatment techniques are very time-dependent. In order to maximize benefit, onset-to-treatment times must be kept to a minimum. A wide range of clinical settings have been used to establish the safety and effectiveness of IV rtPA. Endovascular therapy currently blesses patients who had a poor response to IV r-tPA with a significantly better outcome, but success has only been proven in the setting of highly organized neurovascular interventional services.

Funding Sources: None to report.

Disclosure Statement: None to declare.

References

1. Emberson J. Lees KR. Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet.* 2014;384:1929–35. [PMC free article] [PubMed] [Google Scholar]
2. Rother J. Ford GA. Thijs VN. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. *Cerebrovasc Dis.* 2013;35:313–9. [PubMed] [Google Scholar]
3. Morris DL. Rosamond W. Madden K. Schultz C. Hamilton S. Prehospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. *Stroke.* 2000;31:2585–90. [PubMed] [Google Scholar]
4. Frank B. Grotta JC. Alexandrov AV, et al. Thrombolysis in stroke despite contraindications or warnings? *Stroke.* 2013;44:727–33. [PubMed] [Google Scholar]
5. Whiteley WN. Emberson J. Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. *Lancet Neurol.* 2016;15:925–33. [PubMed] [Google Scholar]
6. Demaerschalk BM. Kleindorfer DO. Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2016;47:581–641. [PubMed] [Google Scholar]
7. Sharma S. Mazya MV. Wahlgren N. Ahmed N. IV thrombolysis in very severe and severe ischemic stroke: results from the SITS-ISTR Registry. *Neurology.* 2016;86:2115. [PubMed] [Google Scholar]
8. Demchuk AM. Hill MD. Barber PA, et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. *Stroke.* 2005;36:2110–5. [PubMed] [Google Scholar]
9. Lindley RI. Wardlaw JM. Whiteley WN, et al. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial. *Stroke.* 2015;46:746–56. [PubMed] [Google Scholar]
10. Liebeskind DS. Alexandrov AV. Advanced multimodal CT/MRI approaches to hyperacute stroke diagnosis, treatment, and monitoring. *Ann N Y Acad Sci.* 2012;1268:1–7. [PMC free article] [PubMed] [Google Scholar]
11. Cheripelli BK. Huang X. MacIsaac R. Muir KW. Interaction of recanalization, intracerebral hemorrhage, and cerebral edema after intravenous thrombolysis. *Stroke.* 2016;47:1761–7. [PubMed] [Google Scholar]
12. Latchaw RE. Alberts MJ. Lev MH, et al. Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. *Stroke.* 2009;40:3646–78. [PubMed] [Google Scholar]
13. European Stroke Organisation (ESO)Executive Committee, ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischaemic attack. *Cerebrovasc Dis.* 2008;25:457–507. 2008. [PubMed] [Google Scholar]
14. Thomalla G. Sobesky J. Kohrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. *Stroke.* 2007;38:313–8. [PubMed] [Google Scholar]
15. Lansberg MG. Albers GW. Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. *Cerebrovasc Dis.* 2007;24:1–10. [PubMed] [Google Scholar]
16. Mazya M. Egido JA. Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. *Stroke.* 2012;43:1524–31. [PubMed] [Google Scholar]

17. Whiteley WN. Emberson J. Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. *Lancet Neurol.* 2016;15:925–33. [PubMed] [Google Scholar]
18. Miller DJ. Simpson JR. Silver B. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. *Neurohospitalist.* 2011;1:138–47. [PMC free article] [PubMed] [Google Scholar]
19. Hurford R. Rezvani S. Kreimei M, et al. Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. *J Neurol Neurosurg Psychiatry.* 2015;86:520–3. [PubMed] [Google Scholar]
20. Zarar A. Khan AA. Adil MM. Qureshi AI. Anaphylactic shock associated with intravenous thrombolytics. *Am J Emerg Med.* 2014;32 113:e3–5. [PubMed] [Google Scholar]
21. The IST-3 collaborative group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. *Lancet.* 2012;379:2352–63. [PMC free article] [PubMed] [Google Scholar]
22. del Zoppo GJ. Poeck K. Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. *Ann Neurol.* 1992;32:78–86. [PubMed] [Google Scholar]
23. Bush CK. Kurimella D. Cross LJ, et al. Endovascular treatment with stent-retriever devices for acute ischemic stroke: a meta-analysis of randomized controlled trials. *PloS One.* 2016;11:e0147287. [PMC free article] [PubMed] [Google Scholar]
24. Fransen PS. Berkhemer OA. Lingsma HF, et al. Time to reperfusion and treatment effect for acute ischemic stroke: a randomized clinical trial. *JAMA Neurol.* 2016;73:190–6. [PubMed] [Google Scholar]
25. Berkhemer OA. van den Berg LA. Fransen PS, et al. The effect of anesthetic management during intra-arterial therapy for acute stroke in MR CLEAN. *Neurology.* 2016;87:656–64. [PubMed] [Google Scholar]
26. Darkhabani Z. Nguyen T. Lazzaro MA, et al. Complications of endovascular therapy for acute ischemic stroke and proposed management approach. *Neurology.* 2012;79:S192–8. [PubMed] [Google Scholar]
27. Goyal M. Demchuk AM. Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015;372:1019–30. [PubMed] [Google Scholar]
28. Berkhemer OA. Fransen PS. Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015;372:11–20. [PubMed] [Google Scholar]
29. Goyal M. Demchuk AM. Hill MD. Endovascular therapy for ischemic stroke. *N Engl J Med.* 2015;372:2366. [PubMed] [Google Scholar]
30. Fiehler J. Cognard C. Gallitelli M, et al. European Recommendations on Organisation of Interventional Care in Acute Stroke (EROICAS) *Int J Stroke.* 2016;11:701–16. [PubMed] [Google Scholar].